Search research articles
Contact Us
Filters
Showing results (101-110 of 153) with videos related to
Page
of 16
Sort By:
NPJ Precision Oncology
|
February 16, 2024
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
Marco Tagliamento, Marie Morfouace, Charalambos Loizides, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 9, 2023
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)
Chantal Decroisette, Laurent Greillier, Hubert Curcio, et al.
Therapeutic Advances in Medical Oncology
|
May 5, 2021
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial <i>versus</i> "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
Isabelle Monnet, Alain Vergnenègre, Gilles Robinet, et al.
The Lancet. Oncology
|
January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
British Journal of Cancer
|
February 12, 2019
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
Elodie Maille, Solenn Brosseau, Vincent Hanoux, et al.
Clinical Lung Cancer
|
July 8, 2019
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort
Solenn Brosseau, Claire Danel, Arnaud Scherpereel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Claire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
Page
of 16
Search research articles
Search
Showing results (101-110 of 153) with videos related to
Sort By:
Page
of 16
NPJ Precision Oncology
|
February 16, 2024
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers
Marco Tagliamento, Marie Morfouace, Charalambos Loizides, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)
|
October 9, 2023
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study)
Chantal Decroisette, Laurent Greillier, Hubert Curcio, et al.
Therapeutic Advances in Medical Oncology
|
May 5, 2021
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial <i>versus</i> "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis
Isabelle Monnet, Alain Vergnenègre, Gilles Robinet, et al.
The Lancet. Oncology
|
January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)
Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.
Journal of Clinical Medicine
|
December 2, 2020
Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
Guillaume Herbreteau, Alexandra Langlais, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2017
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
Federica Grosso, Nicola Steele, Silvia Novello, et al.
British Journal of Cancer
|
February 12, 2019
MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial
Elodie Maille, Solenn Brosseau, Vincent Hanoux, et al.
Clinical Lung Cancer
|
July 8, 2019
Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort
Solenn Brosseau, Claire Danel, Arnaud Scherpereel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Claire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
Page
of 16